Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes

European Journal of Haematology

Volumn 80, Issue 2, 2008, Pages 107-114

  Buccisano, Francesco ^a   Maurillo, Luca ^a   Tamburini, Anna ^a   Del Poeta, Giovanni ^a   Del Principe, Maria Ilaria ^a   Ammatuna, Emanuele ^a   Consalvo, Maria Irno ^a   Campagna, Selenia ^a   Ottaviani, Licia ^a   Sarlo, Chiara ^a   Renzi, Daniela ^a   Faccia, Sabrina ^a   Fraboni, Daniela ^a   Coco, Francesco Lo ^a   Amadori, Sergio ^a   Venditti, Adriano ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Adhesion molecules; Flow cytometry; Intercellular adhesion molecule 1; L selectin; Myelodysplastic syndromes; Secondary acute myeloid leukaemia

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW; CD34 SELECTION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BONE MARROW; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; L-SELECTIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TIME FACTORS;

EID: 38049096094     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00986.x     Document Type: Article

References (41)

1. Verfaille CM. Adhesion receptors as regulators of the hematopoietic process. Blood 1998 92 : 2609 12.
2. Williams DA, Rios M, Stephens C, Patel VP. Fibronectin and VLA-4 in hematopoietic stem cells-microenvironment interactions. Nature 1991 352 : 438 41.
3. Verfaillie CM, McCarthy JB, McGlave PB. Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their adhesion to fibronectin. J Exp Med 1991 164 : 693 703.
4. Miyake K, Weissman IL, Greenberg JS, Kincade PW. Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J Exp Med 1991 173 : 599 607.
5. + cells. Blood 1992 80 : 429 36.
6. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994 84 : 2068 101.
7. Shimamoto T, Ohyaishiki K, Takeshita K. Overexpression of the homeobox gene DLX-7 inhibits apoptosis by induced expression of intercellular adhesion molecule-1. Exp Hematol 2000 28 : 433 41.
8. Kansas GS. Selectins and their ligands: current concept and controversies. Blood 1996 88 : 3259 87.
9. Oshaka A, Saionji K, Igari J, Watanabe N, Iwabuchi K, Nagaoka I. Altered surface expression of effector cells molecules on neutrophils in myelodysplastic syndromes. Br J Haematol 1997 98 : 108 13.
10. Willman CL. Biological and genetic features of the myelodysplastic syndromes. Hematology 2000 1 : 110 7.
11. Ogata K, Nakamura K, Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002 100 : 3887 96.
12. Kawaishi K, Kimura A, Katoh O, Sasaki A, Oguma N, Ihara A, Satow Y. Decreased l-selectin expression in CD34-positive cells from patients with chronic myelocytic leukemia. Br J Haematol 1996 93 : 367 74.
13. 1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood 1998 91 : 3414 22.
14. Graf M, Reif S, Hecht K, Pelka-Fleischer R, Pfister K, Nuessler V, Schmetzer H. Low l-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk. Eur J Haematol 2003 71 : 366 76.
15. Look AT. Molecular pathogenesis of myelodysplastic syndromes. Hematology 2005 1 : 156 60.
16. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996 88 : 4275 87.
17. Mundle SD, Venugopal P, Cartlidge JD, et al. Indication of an involvement of interleukin-1 converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 1996 88 : 2640 7.
18. Graf M, Reif S, Hecht K, Pelka-Fleischer R, Kroell T, Pfister K, Schmetzer H. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol 2005 84 : 287 97. Epub 2004 Dec 7.
19. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002 100 : 2292 302.
20. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. The French-American-British (FAB) co-operative group. Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 1982 51 : 189 99.
21. Greenberg P, Cox C, Le Beau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997 89 : 2079 88.
22. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 1998 83 : 1104 15.
23. Del Canizo MC, Fernandez ME, Lopez A, Vidriales B, Villaron E, Arroyo JL, Ortuno F, Orfao A, San Miguel JF. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 2003 88 : 402 7.
24. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001 98 : 979 87.
25. Maynadie M, Picard F, Husson B, et al. Groupe d'Etude Immunologique des Leucemies (GEIL). Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002 100 : 2349 56.
26. Della Porta MG, Malcovati L, Invernizzi R, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic sindrome. Haematologica 2006 20 : 549 55.
27. Wood BL. Flow cytometric diagnosis of myelodysplasia and myeloproliferative disorders. J Biol Regul Homeost Agents 2004 18 : 141 5.
28. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myeoldysplastic syndromes. Blood 2006 108 : 1037 44.
29. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003 102 : 394 403.
30. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999 340 : 1649 60.
31. Saitoh K, Miura I, Takahashi N, Miura AB. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. Blood 1998 92 : 2886 92.
32. Haase D, Feuring-Buske M, Schafer C, Schoch C, Troff C, Gahn B, Hiddemann W, Wörmann B. Cytogenetic analysis of CD34+ subpopulation in AML and MDS characterized by the expression of CD38 and CD117. Leukemia 1997 11 : 674 9.
33. Nilsson L, Astrand-Grundstrom I, Arvidsson I, Jacobsson B, Hellström-Lindberg E, Hast R, Jacobsen SE. Isolation an characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes. Evidence for involvement at the hematopoietic stem cell level. Blood 2000 96 : 2012 21.
34. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of RAS pathway and leads to aberrant growth in hematopoietic cells. Nat Genet 1996 12 : 144 8.
35. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Takeuchi K, Maki K, Ogawa S, Chiba S, Mitani K, Hirai H. Mutations of the AML1 gene in myelodysplastic syndromes and their functional implications in leukemogenesis. Blood 2000 96 : 3154 60.
36. Ben-Yehuda D, Krichewsky S, Caspi O, et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996 88 : 4296 303.
37. INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998 91 : 2985 90.
38. + myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumor necrosis factor-alpha concentration. Br J Haematol 1997 99 : 625 31.
39. Chen H, Sandler D, Taylor J, Shore DL, Liu E, Bloomfield CD, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) defect. Lancet 1996 347 : 295 7.
40. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000 96 : 3932 8.
41. Delforge M, Raets V, Van Duppen V, Verhoef GEG, Boogaerts MA. Reduced expression of a5b1 integrins on CD34+ marrow progenitors of MDS patients with high levels of apoptosis. Blood 2000 96 : 3601a.